Patent · US Active

Combination of an anti-ED—B fibronectin domain antibody—IL-2 fusion protein and gemcitabine

US7851599B2 · kind B2 · utility

7Cited by

0References

20Claims

0Family size

Assignee

PHILOGEN S.P.A. · IT

Inventors

Andreas Menrad · Berlin, DE
Hans Dietrich Menssen · Berlin, DE
Karola Wagner · Berlin, DE

Key dates

Filing date	Apr 4, 2007
Grant date	Dec 14, 2010
Priority date	—
Expiry date	Jan 10, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/74
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention refers to the use of L19IL2 for treatment of pancreatic cancer. In another embodiment, the invention relates to a combination (i) of a fusion protein, comprising an Interleukin 2 part and an antibody part, specifically recognizing the extra domain B of fibronectin (ED-B-fibronectin), and (ii) gemcitabine.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.